Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Dupixent® (dupilumab) – New indication
June 20, 2025 - Sanofi and Regeneron announced the FDA approval of Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP).